References
- Haioun C, Itti E, Rahmouni A, Brice P, Rain J D, Belhadj K, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376–1381
- Mikhaeel N G, Hutchings M, Fields P A, O'Doherty M J, Timothy A R. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514–1523
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
- Canellos G P. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931–933
- Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186–196
- Hicks R J, Mac Manus M P, Seymour J F. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165–175
- Kantarjian H M, O'Brien S, Smith T L, Cortes J, Giles F J, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561
- Christie D R, Barton M B, Bryant G, Cheuk R, Gebski V, Hornsey J, et al. Osteolymphoma (primary bone lymphoma): an Australian review of 70 cases. Australasian Radiation Oncology Lymphoma Group (AROLG). Aust NZJ Med 1999; 29: 214–219
- Mengiardi B, Honegger H, Hodler J, Exner U G, Csherhati M D, Bruhlmann W. Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. AJR Am J Roentgenol 2005; 184: 185–192
- Israel O, Mekel M, Bar-Shalom R, Epelbaum R, Hermony N, Haim N, et al. Bone lymphoma: 67 Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med 2002; 43: 1295–1303